triple agonist glp 1 Courtesy ref no. 43-Schematic demonstrating the working principle, Retatrutide peptide for weight loss

Under the terms of the alliance, Ascendis will carry out the early development of TransCon product candidates, funded by Novo Nordisk, with the pharma group taking over once they reach the clinical development stage.

Theres also a housekeeping component

Possible side effects are uncommon but may include mild injection site irritation or temporary digestive discomfort

Table of Contents How Retatrutide and Sermorelin Work in the Body Potential Interactions Between Retatrutide and Sermorelin What the Current Evidence and Guidelines Say Risks and Safety Considerations for Combined Use When to Seek Advice from a UK Prescriber or Specialist Alternatives and Next Steps for Weight or Hormone Management Scientific References Frequently Asked Questions How Retatrutide and Sermorelin Work in the Body Retatrutide activates GLP-1, GIP, and glucagon receptors to reduce appetite and body weight, whilst sermorelin stimulates pituitary growth hormone release via the GHRH pathway